Skip to main content
    N

    Nutex Health Inc (NUTX)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ

    $169.70
    -3.97 (-2.29%)

    Market Cap: $1.19B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Nutex Health Inc (NUTX) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Nutex Health (NUTX) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, Nutex Health reported EPS of $5.71, above the $5.53 estimate. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    62%(8/13)
    Avg Surprise
    +20.01%
    Streak
    3 Q

    Upcoming Estimates

    Reports Mar 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$6.03
    Range$5.57 - $6.56
    7 analysts
    Revenue Consensus
    $231.16M
    Range$215.66M - $243.39M
    7 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$7.09
    Range$5.95 - $7.81
    6 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$7.44-4.7%
    60d ago$7.33-3.3%
    30d ago$7.33-3.3%
    7d ago$7.05+0.5%
    Current$7.09
    Revenue Consensus
    $234.93M
    Range$232.10M - $241.10M
    6 analysts

    Next Report

    NUTX has an expected report date of Mar 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 272.2% above the $1.62 reported for the quarter ended Dec 31, 2025.

    NUTX Earnings Call

    The latest NUTX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 13 quarters below that had an estimate, NUTX beat 8, missed 4 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $217.61M, down 18.7% from $267.80M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$5.71$5.53$4.71 - $6.56+3.25%Beat-26.4%65 up, 0 downNov 5, 2026$217.61M
    Jun 30, 2026$9.58$5.26$2.87 - $5.58+82.13%Beat+83.3%52 up, 0 downAug 6, 2026$210.75M
    Mar 31, 2026$5.74$5.56$5.56 - $5.56+3.24%Beat+222.5%10 up, 0 downApr 30, 2026$216.49M
    Dec 31, 2025$1.62$5.56$2.99 - $7.30-70.85%Miss-85.4%31 up, 1 downMar 5, 2026$151.68M
    Sep 30, 2025$7.76$1.95$1.95 - $1.95+297.95%BeatN/A11 up, 0 downOct 22, 2025$267.80M
    Jun 30, 2025$5.23-$5.43-$5.43 - -$5.43+196.25%BeatN/A10 up, 1 downJun 30, 2025$243.99M
    Mar 31, 2025$1.78$3.91$2.83 - $4.98-54.48%MissN/A21 up, 0 downMay 13, 2025$211.79M
    Dec 31, 2024$11.12-$0.12N/AN/AN/AN/AN/A0 up, 0 downMar 31, 2025$257.62M
    Sep 30, 2024-$0.32$0.28-$0.76 - $0.28-214.29%MissN/A20 up, 0 downNov 8, 2024$78.80M
    Jun 30, 2024-$0.15-$0.29-$0.29 - -$0.29+48.28%BeatN/A10 up, 0 downAug 8, 2024$76.08M
    Mar 31, 2024-$0.06N/AN/AN/AN/AN/AN/A0 up, 0 downMay 8, 2024$67.45M
    Dec 31, 2023-$7.50-$0.01N/AN/AN/AN/A10 up, 0 downMar 28, 2024$69.67M
    Sep 30, 2023-$1.25-$1.50N/A+16.67%BeatN/AN/A0 up, 0 downNov 9, 2023$62.72M
    Jun 30, 2023-$1.50-$1.50-$1.50 - $0.000.00%In lineN/A20 up, 0 downAug 9, 2023$58.92M
    Mar 31, 2023-$1.44-$3.00-$3.00 - -$1.50+52.00%BeatN/A20 up, 1 downMay 15, 2023$56.33M
    Dec 31, 2022-$0.02-$0.01-$0.02 - -$0.01-100.00%MissN/A20 up, 0 downMar 2, 2023$53.72M
    Sep 30, 2022-$0.65N/AN/AN/AN/AN/AN/AN/ANov 21, 2022$28.40M
    Jun 30, 2022-$0.03N/AN/AN/AN/AN/AN/AN/AAug 22, 2022$58.05M
    Mar 31, 2022-$0.35N/AN/AN/AN/AN/AN/AN/AApr 1, 2022$79.13M
    Dec 31, 2021-$0.10N/AN/AN/AN/AN/AN/AN/AMar 31, 2022$148.73M
    Sep 30, 2021-$0.04N/AN/AN/AN/A-100.1%N/AN/ANov 15, 2021$117.97M
    Jun 30, 2021-$0.07N/AN/AN/AN/A-101.0%N/AN/AAug 16, 2021$62.81M
    Mar 31, 2021-$1.23N/AN/AN/AN/AN/AN/AN/AApr 2, 2021$2.01M
    Dec 31, 2020-$184.88N/AN/AN/AN/AN/AN/AN/ADec 31, 2020$272.83M
    Sep 30, 2020$50.86N/AN/AN/AN/AN/AN/AN/ANov 16, 2020$350032
    Jun 30, 2020$7.33N/AN/AN/AN/AN/AN/AN/AAug 19, 2020$378588
    Mar 31, 2020-$36.22N/AN/AN/AN/AN/AN/AN/AJun 29, 2020$465630
    Dec 31, 2019-$181.10N/AN/AN/AN/AN/AN/AN/ADec 31, 2019N/A
    Sep 30, 2019-$0.48N/AN/AN/AN/AN/AN/AN/ANov 19, 2019$17592
    Jun 30, 2019-$112.39N/AN/AN/AN/AN/AN/AN/AAug 19, 2019$14387
    Mar 31, 2019-$146.58N/AN/AN/AN/AN/AN/AN/AApr 16, 2019$13532
    Dec 31, 2018-$360.91N/AN/AN/AN/AN/AN/AN/ADec 31, 2018N/A
    Sep 30, 2018-$313.12N/AN/AN/AN/A-107.9%N/AN/ANov 19, 2018$30416
    Jun 30, 2018-$426.76N/AN/AN/AN/AN/AN/AN/AAug 14, 2018$11620
    Mar 31, 2018-$377.35N/AN/AN/AN/AN/AN/AN/AApr 17, 2018$12122
    Sep 30, 2017$3,956.70N/AN/AN/AN/A+866.3%N/AN/ANov 20, 2017$26964
    Jun 30, 2017-$2,105.16N/AN/AN/AN/AN/AN/AN/AAug 18, 2017$19027
    Mar 31, 2017-$371.98N/AN/AN/AN/AN/AN/AN/AMar 31, 2017N/A
    Sep 30, 2016$409.48N/AN/AN/AN/AN/AN/AN/ASep 30, 2016N/A
    Jun 30, 2016-$181.53N/AN/AN/AN/AN/AN/AN/AJun 30, 2016N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $16.39, up 54.7% from the year before. It was -$676.24 for the year ended Dec 31, 2014, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$16.39+54.7%
    Dec 31, 2024$10.59N/A
    Dec 31, 2023-$11.69N/A
    Dec 31, 2022-$1.05N/A
    Dec 31, 2021-$1.44N/A
    Dec 31, 2020-$162.91N/A
    Dec 31, 2019-$440.55N/A
    Dec 31, 2018-$976.76N/A
    Dec 31, 2014-$676.24N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,800 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,79912
    2026Q2Jun 30, 20267,74010
    2026Q1Mar 31, 20265,4409
    2025Q4Dec 31, 20256,2718
    2025Q2Jun 30, 20256,11010
    2025Q1Mar 31, 20254,78710
    2024Q4Dec 31, 20247,75210
    2024Q3Sep 30, 20246,1728

    2026Q3 Earnings Call

    Opening remarks

    Vivian Sanders Moderator Good morning, everyone, and welcome to Nutex Health, Inc.'s Third Quarter 2026 Earnings Call. My name is Vivian Sanders, and I'm happy to serve as your moderator today. We're truly grateful for your participation and your continued interest in our company as we share the highlights of another exceptional quarter. Please note that this call is being recorded for future reference. Joining me this morning are some of our key leaders driving Nutex Health forward: our Chairman and CEO, Dr. Tom Vo; our Chief Financial Officer, Jon Bates; our President, Dr. Warren Hosseinion; and our Chief Operating Officer, Wes Bamburg. Together, they'll provide prepared remarks to give you a comprehensive view of our performance, strategies, and vision, after which we'll open the floor for your questions. Before I turn things over to Dr. Vo, I'd like to take a moment to address a few important points. Today's discussion may include forward-looking statements, which reflect management's current expectations about our future performance. These statements are based on what we know today, but they're subject to risks, uncertainties, and other factors that could cause our actual results to differ from what we'll share. For a deeper dive into these forward-looking statements and the factors that may influence them, I encourage you to review the press release and Form 10-Q filed earlier this week, as well as our various SEC filings. You'll find all the details there. Additionally, we may reference non-GAAP financial measures such as adjusted EBITDA during the call. For those interested in how these metrics reconcile to GAAP standards, please refer to the press release and the Form 10-Q, where we've included that information. With those housekeeping items out of the way, it's my pleasure to hand the call over to Dr. Tom Vo, our Founder and Chief Executive Officer. Dr. Vo, the floor is yours.

    Thomas Vo Chairman and CEO Thank you, Vivian, and good morning, everyone. I'm pleased to join you today to review Nutex Health's third quarter 2026 results. It was another strong quarter with solid financial results, steady collections, important reimbursement developments, and continued growth in hospital volumes. I'll start with our financial and operational performance in the first nine months. For the first three quarters of 2026, total revenue reached $644.9 million, an 11% decrease from $723.6 million for the same period in 2025. Adjusted EBITDA decreased 13% from $243 million to $211.4 million for the first three quarters of 2026. Net income attributable to Nutex increased to $152.9 million for the first three quarters of 2026, a 159% increase from $59 million for the same period in 2025.

    Frequently Asked Questions About NUTX

    When is Nutex Health's next earnings date?

    Nutex Health's next earnings report is expected for Mar 3, 2027.

    Did NUTX beat earnings estimates last quarter?

    Yes. Nutex Health reported EPS of $5.71 for the quarter ended Sep 30, 2026, above the $5.53 estimate, a 3.25% surprise.

    What EPS do analysts expect from NUTX next quarter?

    The consensus EPS estimate for Nutex Health for the quarter ending Dec 31, 2026 is $6.03 from 7 analysts, with estimates from $5.57 to $6.56.

    How often does NUTX beat earnings estimates?

    Nutex Health beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +30.40%.